Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8–7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Raderer, M, Hamilton, G, Kurtaran, A, Valencak, J, Haberl, I, Hoffmann, O, Kornek, G V, Vorbeck, F, Hejna, M H L, Virgolini, I, Scheithauer, W
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1999
Assuntos:
Regular Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362412/
https://ncbi.nlm.nih.gov/pubmed/10027326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690084
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados